These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 39019012

  • 21. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H, Berrou J, Dupont M, Kaci A, Ehlert JE, Weber H, Baruchel A, Paublant F, Prudent R, Gardin C, Dombret H, Braun T.
    Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
    [Abstract] [Full Text] [Related]

  • 22. Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
    Wang P, Zhang Y, Xiang R, Yang J, Xu Y, Deng T, Zhou W, Wang C, Xiao X, Wang S.
    Cancer Res; 2024 Mar 15; 84(6):905-918. PubMed ID: 38231480
    [Abstract] [Full Text] [Related]

  • 23. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD.
    Blood; 2013 Nov 21; 122(22):3607-15. PubMed ID: 24046014
    [Abstract] [Full Text] [Related]

  • 24. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
    Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F.
    J Clin Oncol; 2024 May 01; 42(13):1499-1508. PubMed ID: 38277619
    [Abstract] [Full Text] [Related]

  • 25. Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib.
    Ha YN, Song S, Orlikova-Boyer B, Cerella C, Christov C, Kijjoa A, Diederich M.
    Mar Drugs; 2020 Jan 16; 18(1):. PubMed ID: 31963113
    [Abstract] [Full Text] [Related]

  • 26. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J, Jia MY, Fang WY, Chen XJ, Mu LL, Wang ZY, Shen Y, Xiang RF, Wang LN, Wang L, Jiang CH, Jiang JL, Zhang WJ, Sun YD, Chang L, Gao WH, Wang Y, Li JM, Hong DL, Liang AB, Hu J.
    Blood; 2020 Apr 23; 135(17):1472-1483. PubMed ID: 32315388
    [Abstract] [Full Text] [Related]

  • 27. A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib.
    Li KX, Wu HY, Pan WY, Guo MQ, Qiu DZ, He YJ, Li YH, Yang DH, Huang YX.
    Mol Cancer; 2022 Mar 04; 21(1):66. PubMed ID: 35246156
    [Abstract] [Full Text] [Related]

  • 28. Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways.
    Yu M, Fang ZX, Wang WW, Zhang Y, Bu ZL, Liu M, Xiao XH, Zhang ZL, Zhang XM, Cao Y, Wang YY, Lei H, Xu HZ, Wu YZ, Liu W, Wu YL.
    Acta Pharmacol Sin; 2021 Apr 04; 42(4):604-612. PubMed ID: 32694757
    [Abstract] [Full Text] [Related]

  • 29. Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways.
    Zhao MN, Su L, Song F, Wei ZF, Qin TX, Zhang YW, Li W, Gao SJ.
    Acta Haematol; 2024 Apr 04; 147(3):310-324. PubMed ID: 37926079
    [Abstract] [Full Text] [Related]

  • 30. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.
    Ballesta-López O, Solana-Altabella A, Megías-Vericat JE, Martínez-Cuadrón D, Montesinos P.
    Future Oncol; 2021 Jan 04; 17(2):215-227. PubMed ID: 32975130
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia.
    Li D, Li T, Shang Z, Zhao L, Xu Q, Tan J, Qin Y, Zhang Y, Cao Y, Wang N, Huang L, Zhu X, Zhou K, Chen L, Li C, Xie T, Yang Y, Wang J, Zhou J.
    Signal Transduct Target Ther; 2020 Mar 13; 5(1):21. PubMed ID: 32296014
    [Abstract] [Full Text] [Related]

  • 34. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
    Ando T, Sano H, Yokoo M, Kusaba K, Kidoguchi K, Yamaguchi K, Katsuya H, Yoshihara S, Kubota Y, Kojima K, Kimura S.
    Int J Hematol; 2020 Aug 13; 112(2):249-253. PubMed ID: 32185622
    [Abstract] [Full Text] [Related]

  • 35. In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia.
    Carranza-Aranda AS, Jave-Suárez LF, Flores-Hernández FY, Huizar-López MDR, Herrera-Rodríguez SE, Santerre A.
    Mol Med Rep; 2024 Dec 13; 30(6):. PubMed ID: 39392050
    [Abstract] [Full Text] [Related]

  • 36. [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
    Fukuoka K, Tsumura Y, Noguchi J, Sugawa M, Takaki T, Hiraki T, Inoue K, Mitani Y, Tomita O, Oshima K, Yanagi M, Isobe K, Mori M, Arakawa Y, Koh K.
    Rinsho Ketsueki; 2020 Dec 13; 61(4):322-326. PubMed ID: 32378574
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.